

## 8<sup>th</sup> ANNUAL INTERNATIONAL MEETING

# BIOMARKERS SUMMIT IN UROLOGICAL CANCERS

## OCTOBER 27/28, 2023 FAD WEBINAR

SCIENTIFIC DIRECTOR **DR. UGO DE GIORGI** HEAD GU UNIT - IRST IRCCS - MELDOLA - I

10.27.2023

15.00 **Introduction and presentation** Giovanni Martinelli *IRCCS IRST Scientific Director, Meldola* - Ugo De Giorgi, *Clinical and Experimental Oncology Unit*

### I SESSION **PROSTATE CANCER – NEW CHALLENGES AND CLINICAL APPLICATIONS**

Moderators: Nicole Brighi *IRCCS IRST, Meldola* - Ugo De Giorgi *IRCCS IRST, Meldola* - Pasquale Rescigno *Newcastle University, UK*

15.10 **Selecting PARPi and radionuclide therapies for mCRPC** Ugo De Giorgi *IRCCS IRST, Meldola*

15.30 **An update on liquid biopsy for prostate cancer: progress and pitfalls.** Pasquale Rescigno *Newcastle University, UK*

15.50 **Discussion on the topics discussed**

16.10 **ARSI in nmCRPC and mCRPC: clinical vs molecular factors** Piero Nuzzo *Cornell University, NY, USA*

16.25 **Improving bone health in patients with metastatic prostate cancer** Maria Concetta Cursano *IRCCS IRST, Meldola*

16.40 **Discussion on the topics discussed**

17.00 **Escalation/de-escalation for metastatic hormono-sensitive prostate cancer** Neeraj Agarwal *University of Utah, Salt Lake City, USA*

17.20 **Escalation/de-escalation for high-risk biochemical relapse** Stephen Freedland *Cedars-Sinai Medical Center, Los Angeles, USA*

17.40 **Discussion on the topics discussed**

18.00 **Testicular cancer – novel biomarkers for old treatments?** Milena Urbini *IRCCS IRST, Meldola*

18.15 **Movember** Paolo Grillandi *IOR, Forlì*

18.30 **Conclusions** Ugo De Giorgi *IRCCS IRST, Meldola*

10.28.23

09.20 **Introduction and presentation** Ugo De Giorgi, *Clinical and Experimental Oncology Unit*

### II SESSION **RENAL CELL CARCINOMA AND UROTHELIAL CANCER**

Moderators: Ugo De Giorgi *IRCCS IRST, Meldola* - Giuseppe Procopio *IRCCS IstNazTumori, Milano*

09.30 **Contemporary combination therapies for patients with metastatic renal cell carcinoma with intermediate/poor prognosis**

Manuela Schmidinger *Comprehensive Cancer Center, Medical University, Vienna, A*

10.00 **Treatment landscape of metastatic renal cell cancer with good prognosis** Bernard Escudier *Gustave Roussy Institute, Villejuif, F*


10.30 **Discussion on the topics discussed**

11.00 **Prognostic scores and algorithms for immunotherapy in bladder cancer** Giuseppe Banna *Portsmouth Hospitals University NHS, Portsmouth, UK*

11.30 **Future prospects of targeted therapies and antibody-drug conjugates in urothelial cancer** Simon J. Crabb *University of Southampton, UK*

12.00 **Discussion on the topics discussed**

12.30 **Conclusion** Ugo De Giorgi *IRCCS IRST, Meldola*



## 8<sup>th</sup> ANNUAL INTERNATIONAL MEETING

# BIOMARKERS SUMMIT IN UROLOGICAL CANCERS

## OCTOBER 27/28, 2023 FAD WEBINAR

SCIENTIFIC DIRECTOR **DR. UGO DE GIORGI** HEAD GU UNIT - IRST IRCCS - MELDOLA - I



### REGISTRATION:

Registration is free of charge. Please complete the process to register at our site [www.mitcongressi.it](http://www.mitcongressi.it)

**9 CME FOR ITALIAN PARTICIPANTS ONLY** **Medical specialties:** Biology, Pharmacy, Biomedical Technician, Radiology Technician, Medical Physics, Allergology and Immunology, Endocrinology, Medical Genetics, Internal medicine, Nephrology, Oncology, Radiotherapy, General surgery, Urology, Anatomic and Pathology, Anesthesia, Pharmacology and toxicology, Medical genetics laboratory, Nuclear medicine, Radiodiagnostic oncology, Medical hospital management, Palliative care, Psychotherapy, Psychology, Nursing

### CME INSTRUCTIONS

The CME Questionnaire and Certificate of Participation will be available online by accessing our platform in the "My courses" section of your reserved area. For the purpose of acquiring credits, you will need 90% in person attendance and a score of 75% or higher on the learning assessment questionnaire. You must have both in person attendance and questionnaire completion to obtain credit. **The deadline for the completion of the ECM assessment questionnaire and the course approval questionnaire is set within 72 hours from the end of the course.**

### SEGRETERIA ORGANIZZATIVA

 Mi&T srl Centro Direzionale Bolomna Via Guelfa, 5 - 40138 Bologna  
info@mitcongressi.it - www.mitcongressi.it

UNRESTRICTED GRANT BY  
PLATINUM SPONSOR



GOLD SPONSOR



SILVER SPONSOR

